ClinicalTrials.Veeva

Menu

Effects of Chest Wall Elastance on Pulmonary Mechanics of Acute Respiratory Failure (ARF)

S

Southeast University, China

Status

Completed

Conditions

Airway Pressure Stress Index
Acute Respiratory Failure
Chest Wall Elastance
Transpulmonary Pressure Stress Index

Study type

Observational

Funder types

Other

Identifiers

NCT02196870
Chest wall Elastance in ARF

Details and patient eligibility

About

Patients with chest wall elastance increasing could worsen lung function. Increasing of chest wall elastance plays a great role in lung mechanics, and could influence mechanical ventilation settings. Therefore, It could help the physicians to find appropriate indicators and optimize the treatments of ARF patients to explore the mechanisms of lung mechanics changse in the patients with high chest wall elastance.

Full description

Mechanical ventilation(MV) is an important treatment for acute respiratory failure(ARF) patients, could improve hypoxemia, maintain lung volume and promote alveolar opening. However, because of barotrauma, volutrauma and biotrauma, MV could cause or aggravate acute lung injury not only in acute respiratory distress syndrome(ARDS) patients, but in patients with normal lung function1,2.

Patients with chest wall elastance increasing could worsen lung function. Increasing of chest wall elastance plays a great role in lung mechanics, and could influence mechanical ventilation settings. Therefore, It could help the physicians to find appropriate indicators and optimize the treatments of ARF patients to explore the mechanisms of lung mechanics changse in the patients with high chest wall elastance.

The present study is set out to examine the effects of high chest wall elastance on changes of lung mechanics and the correlation of airway pressure(Paw) stress index and transpulmonary pressure(PL) stress index.

Enrollment

12 patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • ARF
  • mechanical ventilation
  • cardiovascular stable

Exclusion criteria

  • age < 18y or > 85y
  • pregnancy
  • COPD or chronic pulmonary disease

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems